{"id":4827,"date":"2021-07-17T16:44:48","date_gmt":"2021-07-17T22:44:48","guid":{"rendered":"https:\/\/www.epicore.ualberta.ca\/home\/\/?p=4827"},"modified":"2023-01-18T13:20:59","modified_gmt":"2023-01-18T20:20:59","slug":"map-ap","status":"publish","type":"post","link":"https:\/\/www.epicore.ualberta.ca\/home\/map-ap\/","title":{"rendered":"MAP-AP Study &#8211; Mental Health Assessment and Prescribing by Alberta Pharmacists"},"content":{"rendered":"<h4 style=\"text-align: center;\"><b>MAP-AP Study &#8211; Mental Health Assessment and Prescribing by Alberta Pharmacists\u00a0<\/b><br \/>\n<\/h4>\n<h5><b>Purpose:<\/b><\/h5>\n<h5><span style=\"font-weight: 400;\">MAP-AP tracks and quantifies the impact of community pharmacists (practicing at the<br \/>\n        full scope within Alberta) on the management of patients with newly diagnosed Major Depressive Disorder (MDD)<br \/>\n        and\/or Generalized Anxiety Disorder (GAD), compared to usual care<\/span><\/h5>\n<h5><\/h5>\n<h5><b>Setting:\u00a0<\/b><\/h5>\n<h5><span style=\"font-weight: 400;\">Community Pharmacies in\u00a0Alberta<\/span><\/h5>\n<h5><\/h5>\n<h5><b>Participants:\u00a0<\/b><\/h5>\n<h5><span style=\"font-weight: 400;\">Adult patients with new diagnosis and prescribed medication for the management of<br \/>\n        Major Depressive Disorder (MDD) and\/or Generalized Anxiety Disorder (GAD)<\/span><\/h5>\n<h5><\/h5>\n<h5><b>Study Design:\u00a0<\/b><\/h5>\n<h5><span style=\"font-weight: 400;\">Multi-centre randomized controlled trial<\/span><\/h5>\n<h5><span style=\"font-weight: 400;\">This study will last approximately 18 months, with each participant is enrolled for<br \/>\n        6 months<\/span><\/h5>\n<h5><\/h5>\n<h5><b>Control Group (Standard Care)<\/b><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Receives standard care from both physician and pharmacist\u00a0<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Pharmacist provides brochure from Alberta Health Services Access Mental<br \/>\n                Health\u00a0<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Completes the PHQ-9 and\/or GAD-7 questionnaire at enrollment (month 0) and<br \/>\n                prior to their 6 month in-person appointment at the end of study involvement\u00a0<\/span><\/h5>\n<\/li>\n<\/ul>\n<h5><\/h5>\n<h5><b>Intervention (Pharmacist Full Scope Interventions)\u00a0<\/b><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Same as Control group but may receive additional pharmacist involvement,<br \/>\n                which may involve:\u00a0<\/span><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Pharmacist-initiated clinical assessment<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Identification of adverse drug effects, drug interactions, or severe<br \/>\n                        deterioration (i.e. suicide attempt)<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Pharmacist-initiated drug dose adjustments, discontinuation of<br \/>\n                        medication, or prescribing adjunctive therapy<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Pharmacist-initiated collaboration with prescribing physicians<br \/>\n                        regarding medication therapy<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Medication counselling and educational support<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Pharmacist-initiated interim follow-up interviews with patients over<br \/>\n                        the telephone\/telehealth and\/or in person<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Discussion with the prescribing physician to facilitate patient<br \/>\n                        referral to non-pharmacotherapy management resources (e.g. psychologist)\u00a0<\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Completes the PHQ-9 and\/or GAD-7 questionnaire at enrollment (month 0),<br \/>\n                month 1, month 3, and prior to their 6 month in-person appointment at the end of study<br \/>\n                involvement\u00a0<\/span><\/h5>\n<\/li>\n<\/ul>\n<h5><\/h5>\n<h5><b>Outcomes<\/b><\/h5>\n<ul>\n<li>\n<h5><b>Primary Outcome <\/b><span style=\"font-weight: 400;\">is the mean score difference in PHQ-9 and GAD-7<br \/>\n                scores from baseline to end of study participation between the intervention and control groups<\/span><br \/>\n        <\/h5>\n<\/li>\n<\/ul>\n<h5><\/h5>\n<ul>\n<li>\n<h5><b>Secondary Outcomes:<\/b><\/h5>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Difference in proportion of participants achieving clinically<br \/>\n                        significant treatment response for PHQ-9 and \/or GAD-7 between groups at the end of study<br \/>\n                        period\u00a0<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Difference in proportion of participants achieving remission for<br \/>\n                        PHQ-9 and \/or GAD-7 between groups at the end of study period\u00a0<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Difference in proportion in self-reported safety concerns during the<br \/>\n                        study period between groups<\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h5><\/h5>\n<h5><b>Rationale:<\/b><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Stigma still presents as a major barrier to accessing care for mental health<br \/>\n                disorders<\/span><\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Bloom Program piloted in Nova Scotia revealed positive patient benefits when<br \/>\n                community pharmacists are able to practice to their full scope for patients with mental health<br \/>\n                conditions&#8211;highlighting greater collaborative practice and comprehensive support for patients\u00a0<\/span><br \/>\n        <\/h5>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Alberta pharmacists operate with the most expansive scope of practice in<br \/>\n                Canada, including additional prescribing authority (APA) and lab monitoring&#8211;which places community<br \/>\n                pharmacists in a unique position to expand their involvement in the management of patients with MDD and<br \/>\n                GAD<\/span><\/h5>\n<\/li>\n<\/ul>\n<h5><\/h5>\n<h5><b>Research Team<\/b><\/h5>\n<h5><span style=\"font-weight: 400;\">Primary Investigators\u00a0<\/span><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Dr. Yazid Al Hamarneh, BSc (Pharm), PhD, CDM, Department of Medicine<\/span><br \/>\n        <\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">\u00a0<\/span><a href=\"mailto:yazid.alhamarneh@ualberta.ca\"><span\n                            style=\"font-weight: 400;\">yazid.alhamarneh@ualberta.ca<\/span><\/a><span\n                        style=\"font-weight: 400;\"> (780) 492-9608<\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\">\n<h5><span style=\"font-weight: 400;\">Dr. Matt Chow, BSc Pharm, BSc Biology, PharmD, Alberta Health<br \/>\n                Services<\/span><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5><a href=\"mailto:mchow1@ualberta.ca\"><span\n                            style=\"font-weight: 400;\">mchow1@ualberta.ca<\/span><\/a><span style=\"font-weight: 400;\">\u00a0<br \/>\n                        (587) 999-0778<\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h5>Resources:<\/h5>\n<table>\n<tbody>\n<tr>\n<td>\n<h5><b>1. MAP-AP Study<\/b><\/h5>\n<\/td>\n<td>\n<ol type=\"a\">\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Mental%20Health%20Assessment%20and%20Prescribing%20by%20Alberta%20Pharmacists%20(MAP-AP)%20STUDY%20PROTOCOL%20(REB%20ID%20Pro00093776).pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">MAP-AP Study Protocol<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP%20FLOWSHEET%20(2).pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">MAP-AP Overview Summary<br \/>\n                                    Flowsheet<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/youtu.be\/GkilWSLwTHs\" target=\"\u201d_blank\u201d\"><span\n                                    style=\"font-weight: 400;\">MAP-AP Overview Video (video)<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Alberta%20Health%20Services%20Zone%20Map.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Alberta Health Services Zone<br \/>\n                                    Map<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Alberta%20North%20Zone-Important%20Contact%20Information.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Alberta North Zone &#8211; Important Contact<br \/>\n                                    Information<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Alberta%20Edmonton%20Zone-Important%20Contact%20Information.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Alberta Edmonton Zone &#8211; Important<br \/>\n                                    Contact Information<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Alberta%20Central%20Zone-Important%20Contact%20Information.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Alberta Central Zone &#8211; Important<br \/>\n                                    Contact Information<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Alberta%20Calgary%20Zone-Important%20Contact%20Information.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Alberta Calgary Zone &#8211; Important<br \/>\n                                    Contact Information<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Alberta%20South%20Zone-Important%20Contact%20Information.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Alberta South Zone &#8211; Important Contact<br \/>\n                                    Information<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP%20Screening%20Tool%20for%20Participant%20Recruitment%20(REB%20ID%20Pro00093776).pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Screening Tool for Participant<br \/>\n                                    Recruitment<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/End of Study v2.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">End of Study Form<\/span><\/a><\/h5>\n<\/li>\n<\/ol>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<h5>\u00a02.\u00a0<b>Consent forms <\/b><\/h5>\n<\/td>\n<td>\n<ol type=\"a\">\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP%20Formal%20Informed%20Consent%20Form%20(REB%20ID%20Pro00093776).pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Patient Formal Informed Consent<br \/>\n                                    Form\u00a0<\/span><\/a><\/h5>\n<\/li>\n<li style=\"font-weight: 400; text-align: left;\">\n<h5><a href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP%20Notification%20Letter%20for%20Physicians%20(REB%20ID%20Pro00093776).pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Notification Letter for<br \/>\n                                    Physicians\u00a0<\/span><\/a><\/h5>\n<\/li>\n<\/ol>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<h5><b>3. Pre\/Post test resources<\/b><\/h5>\n<\/td>\n<td>\n<ol type=\"a\">\n<li style=\"font-weight: 400;\">\n<h5 style=\"text-align: left;\">Presentation Videos Playlist <a\n                                href=\"https:\/\/www.youtube.com\/playlist?list=PLMre7LGAnl723GD8jmQOjcNhePDxXm5Vz\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">(Videos)<\/span><\/a><\/h5>\n<ul>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"> Major Depressive<br \/>\n                                        Disorder<\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"> Generalized Anxiety<br \/>\n                                        Disorder<\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"> Switching<br \/>\n                                        Medications<\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"> Managing Adverse<br \/>\n                                        effects<\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\">Presentations<\/h5>\n<ul>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP_Major_Depressive_Disorder_Final[1].pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Major Depressive<br \/>\n                                                Disorder<\/span><\/a><\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP_Generalized_Anxiety_Disorder[2].pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Generalized Anxiety<br \/>\n                                                Disorder<\/span><\/a><\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP_Switching_Medications[1].pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Switching<br \/>\n                                                Medications\u00a0<\/span><\/a><\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP_Adverse_Effect_Management[1].pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Managing Adverse<br \/>\n                                                effects<\/span><\/a><\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\">Presentation topic summaries<\/h5>\n<ul>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/Major%20depressive%20disorder_%20summary.pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Major Depressive<br \/>\n                                                Disorder<\/span><\/a><\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/generalized%20anxiety%20disorder%20summary.pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Generalized Anxiety<br \/>\n                                                Disorder<\/span><\/a>\u00a0<\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/switching%20medications_%20summary.pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Switching<br \/>\n                                                Medications<\/span><\/a><\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\"><a\n                                            href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/adverse%20effects_%20summary.pdf\"\n                                            target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">Managing Adverse<br \/>\n                                                effects<\/span><\/a><\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;\">\n<h5 style=\"text-align: center;\"><b>4. Other Resources<\/b><\/h5>\n<\/td>\n<td>\n<ol type=\"a\">\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\">\u00a0<\/span><a\n                                href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP%20Participant%20Questionnaires%20-%20Paper%20Version%20(REB%20ID%20Pro00093776).pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">MAP-AP Participant<br \/>\n                                    Questionnaire<\/span><\/a><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><a\n                                href=\"https:\/\/www.epicore.ualberta.ca\/documents\/MAP-AP\/MAP-AP-Pharmacist%20Case%20Report%20Form-REB%20ID%20Pro00093776.pdf\"\n                                target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">MAP-AP Case report form<br \/>\n                                    paper-copy<\/span><\/a><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\">Generalized Anxiety Disorder 7<br \/>\n                                Question Monitoring tool (GAD-7)\u00a0<\/span><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5 style=\"text-align: left;\"><a\n                                        href=\"https:\/\/www.mdcalc.com\/gad-7-general-anxiety-disorder-7\"\n                                        target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">MDCalc Online<br \/>\n                                            Resource<\/span><\/a><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\">Patient Health Questionnaire 9<br \/>\n                                Question Monitoring tool (PHQ-9)<\/span><\/h5>\n<ul>\n<li style=\"font-weight: 400;\">\n<h5 style=\"text-align: left;\"><a\n                                        href=\"https:\/\/www.mdcalc.com\/phq-9-patient-health-questionnaire-9\"\n                                        target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">MDCalc Online<br \/>\n                                            Resource<\/span><\/a><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\">MAP-AP Standard Operating<br \/>\n                                Procedures Playlist <a\n                                    href=\"https:\/\/www.youtube.com\/playlist?list=PLMre7LGAnl72UI8M6R3ZArPFPQmVbOj4y\"\n                                    target=\"\u201d_blank\u201d\"><span style=\"font-weight: 400;\">(Videos)<\/span><\/a><\/span><\/h5>\n<ul>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\">MAP-AP Study&#8211;Standard<br \/>\n                                        Operating Procedures<\/span><\/h5>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><span style=\"font-weight: 400;\">MAP-AP Study&#8211;Redcap<br \/>\n                                        walkthrough<\/span><\/h5>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<h5 style=\"text-align: left;\"><a href=\"https:\/\/www.switchrx.com\/\" target=\"\u201d_blank\u201d\">SwitchRX<\/a><\/h5>\n<\/li>\n<\/ol>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>MAP-AP Study &#8211; Mental Health Assessment and Prescribing by Alberta Pharmacists\u00a0 Purpose: MAP-AP tracks and quantifies the impact of community pharmacists (practicing at the full scope within Alberta) on the management of patients with newly diagnosed Major Depressive Disorder (MDD) and\/or Generalized Anxiety Disorder (GAD), compared to usual care Setting:\u00a0 Community Pharmacies in\u00a0Alberta Participants:\u00a0 Adult [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[28],"tags":[],"_links":{"self":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts\/4827"}],"collection":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/comments?post=4827"}],"version-history":[{"count":159,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts\/4827\/revisions"}],"predecessor-version":[{"id":5354,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts\/4827\/revisions\/5354"}],"wp:attachment":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/media?parent=4827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/categories?post=4827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/tags?post=4827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}